Midatech enters into research collaboration with Dr Reddy’s Laboratories Ltd (Dr Reddy’s”)
Midatech Pharma’s next generation drug delivery technologies for comprehensively improving bio-delivery and bio-distribution to be applied to existing medicines in collaboration with Dr Reddy’s Laboratories.
Cardiff, UK, 8 June 2020: Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, today announces it has entered into a research collaboration with Dr Reddy’s, one of the global pharmaceutical companies, committed to accelerating access to affordable and innovative medicines.
Midatech will deploy its in-house expertise and proprietary drug delivery platforms towards comprehensive improvement of bio-delivery and bio-distribution of medicines nominated by Dr Reddy’s. Novel products arising from the collaboration are expected to benefit from precision clinical performance and advanced manufacturing technology and, critically, it is anticipated will advance the joint mission of both companies to make medicines that enable treatments, to address unmet patient needs and strive towards ‘Good Health’.
Sam Barker, Director of Business Development of Midatech, said: “This partnership with Dr Reddy’s is further recognition of the power of Midatech Pharma’s unique drug delivery technology to improve and expand treatment options for patients. We are delighted to be able to combine our technology with innovative industry partners, such as Dr Reddy’s, potentially enabling the unique qualities of this technology to reach beyond our own internal development pipeline for the benefit of all patients.”
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).